著者

Thi Thu Thao KHONG Takashi NAKADA Yasuhiko NAKASHIMA

出版者

The Institute of Electronics, Information and Communication Engineers

雑誌

IEICE Transactions on Information and Systems (ISSN:09168532)

巻号頁・発行日

vol.E105.D, no.7, pp.1308-1319, 2022-07-01 (Released:2022-07-01)

参考文献数

38

---

We introduce a hybrid Bayesian-convolutional neural network (hyBCNN) for improving the robustness against adversarial attacks and decreasing the computation time in the Bayesian inference phase. Our hyBCNN models are built from a part of BNN and CNN. Based on pre-trained CNNs, we only replace convolutional layers and activation function of the initial stage of CNNs with our Bayesian convolutional (BC) and Bayesian activation (BA) layers as a term of transfer learning. We keep the remainder of CNNs unchanged. We adopt the Bayes without Bayesian Learning (BwoBL) algorithm for hyBCNN networks to execute Bayesian inference towards adversarial robustness. Our proposal outperforms adversarial training and robust activation function, which are currently the outstanding defense methods of CNNs in the resistance to adversarial attacks such as PGD and C&W. Moreover, the proposed architecture with BwoBL can easily integrate into any pre-trained CNN, especially in scaling networks, e.g., ResNet and EfficientNet, with better performance on large-scale datasets. In particular, under l∞ norm PGD attack of pixel perturbation ε=4/255 with 100 iterations on ImageNet, our best hyBCNN EfficientNet reaches 93.92% top-5 accuracy without additional training.

著者

Takashi Nakada Kiyoshi Sugihara Takahiro Jikoh Yuki Abe Toshinori Agatsuma

出版者

The Pharmaceutical Society of Japan

雑誌

Chemical and Pharmaceutical Bulletin (ISSN:00092363)

巻号頁・発行日

vol.67, no.3, pp.173-185, 2019-03-01 (Released:2019-03-01)

参考文献数

82

被引用文献数

98 230

---

A major limitation of traditional chemotherapy for cancer is dose-limiting toxicity, caused by the exposure of non-tumor cells to cytotoxic agents. Use of molecular targeted drugs, such as specific kinase inhibitors and monoclonal antibodies, is a possible solution to overcome this limitation and has achieved clinical success so far. Use of an antibody–drug conjugate (ADC) is a rational strategy for improving efficacy and reducing systemic adverse events. ADCs use antibodies selectively to deliver a potent cytotoxic agent to tumor cells, thus drastically improving the therapeutic index of chemotherapeutic agents. Lessons learned from clinical failure of early ADCs during the 1980s to 90s have recently led to improvements in ADC technology, and resulted in the approval of four novel ADCs. Nonetheless, further advances in ADC technology are still required to streamline their clinical efficacy and reduce toxicity. [fam-] Trastuzumab deruxtecan (DS-8201a) is a next-generation ADC that satisfies these requirements based on currently available evidence. DS-8201a has several innovative features; a highly potent novel payload with a high drug-to-antibody ratio, good homogeneity, a tumor-selective cleavable linker, stable linker-payload in circulation, and a short systemic half-life cytotoxic agent in vivo; the released cytotoxic payload could exert a bystander effect. With respect to its preclinical profiles, DS-8201a could provide a valuable therapy with a great potential against HER2-expressing cancers in clinical settings. In a phase I trial, DS-8201a showed acceptable safety profiles with potential therapeutic efficacy, with the wide therapeutic index.

著者

Naoki IZUTSU Daisuke AKITA Hideyuki FUKE Issei IIJIMA Yoichi KATO Jiro KAWADA Kiyoho MATSUSHIMA Yukihiko MATSUZAKA Eiichi MIZUTA Takashi NAKADA Naoki NONAKA Yoshitaka SAITO Atsushi TAKADA Keisuke TAMURA Kazuhiko YAMADA Tetsuya YOSHIDA

出版者

THE JAPAN SOCIETY FOR AERONAUTICAL AND SPACE SCIENCES

雑誌

TRANSACTIONS OF THE JAPAN SOCIETY FOR AERONAUTICAL AND SPACE SCIENCES, AEROSPACE TECHNOLOGY JAPAN (ISSN:18840485)

巻号頁・発行日

vol.8, no.ists27, pp.Pm_7-Pm_13, 2010 (Released:2010-12-29)

参考文献数

1

被引用文献数

1 1

---

A zero-pressure balloon used for scientific observation in the stratosphere has an unmanageable limitation that its floating altitude decreases during a nighttime because of temperature drop of the lifting gas. Since a super-pressure balloon may not change its volume, the lifetime can extend very long. We had introduced so called the ‘lobed-pumpkin’ type of super-pressure balloon that can realize a full-scale long-duration balloon and it will be in practical use in the very near future. As for larger super-pressure balloons, however, we still have some potential difficulties to be resolved. We here propose a new design suitable for a larger super-pressure balloon, which is roughly ‘lobed pumpkin with lobed cylinder’ and can adapt a single design for balloons of a wide range of volumes. Indoor inflation tests were successfully carried out with balloons designed and made by the method. It has been shown that the limit of the resisting pressure differential for a new designed balloon is same as that of a normal lobed-pumpkin balloon.